journal article·2024-09Open access

Interfacial Denaturation at the Droplet Simplifies the Formation of Drug‐Loaded Protein Nanocapsules to Enhance Immune Response of Cells

Sharafudheen Pottanam Chali, Jinhong Kang, Michael Fichter, Kai Robert Speth, Volker Mailänder, Katharina Landfester

Advanced Science· Volume 11· Issue 34

Abstract

Abstract Nanocapsules enable multicomponent encapsulation of therapeutic cargoes with high encapsulation content and efficiency, which is vital for cancer immunotherapy. In the past, chemical crosslinking is used to synthesize nanocapsules, which can impede the regulatory approval process. Therefore, a new class of protein nanocapsules is developed by eliminating the need for chemical crosslinking by utilizing protein denaturation through a process that is referred to as “baking at the droplet interface”. Such protein nanocapsules with antigens incorporated in the shell and a combination of encapsulated drugs showed an enhancement in the immune response of cells.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Proteins in Food Systems · Bacteriophages and microbial interactions · Micro and Nano Robotics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Max Planck Institute for Polymer Research Ackermannweg 10 55128 Mainz Germany

Department of Dermatology University Medical Center Mainz Langenbeckstraße 1 55131 Mainz Germany

Funding

Deutsche Forschungsgemeinschaft

References (48)

Show source-provided references
1. 10.1002/anie.20190748410.1002/anie.201907484 ↗
2. 10.1038/s41563-021-01047-710.1038/s41563-021-01047-7 ↗
3. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
4. 10.1016/j.jconrel.2021.03.04310.1016/j.jconrel.2021.03.043 ↗
5. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
6. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
7. 10.1002/advs.20210069410.1002/advs.202100694 ↗
8. 10.1016/j.addr.2007.03.01210.1016/j.addr.2007.03.012 ↗
9. 10.1016/j.jconrel.2012.04.03610.1016/j.jconrel.2012.04.036 ↗
10. Verma D. · J. Pharm. · 2018 · 2018
11. 10.1002/anie.20221609710.1002/anie.202216097 ↗
12. 10.1002/anie.20090072310.1002/anie.200900723 ↗
13. 10.1021/acs.chemrev.5b0056710.1021/acs.chemrev.5b00567 ↗
14. 10.1039/D2NH00243D10.1039/D2NH00243D ↗
15. 10.1039/D1TB01368H10.1039/D1TB01368H ↗
16. 10.1021/bm501691510.1021/bm5016915 ↗
17. 10.1039/C7NH00062F10.1039/C7NH00062F ↗
18. 10.1042/bj2002067610.1042/bj20020676 ↗
19. 10.1021/mp300182710.1021/mp3001827 ↗
20. 10.1073/pnas.88.17.770810.1073/pnas.88.17.7708 ↗
21. 10.1038/160190a010.1038/160190a0 ↗
22. 10.1039/C7BM00411G10.1039/C7BM00411G ↗
23. 10.1038/nsmb.233010.1038/nsmb.2330 ↗
24. 10.1016/j.jpha.2016.02.00410.1016/j.jpha.2016.02.004 ↗
25. 10.1529/biophysj.106.10351510.1529/biophysj.106.103515 ↗
26. 10.1002/pro.362210.1002/pro.3622 ↗
27. 10.1016/j.jconrel.2018.09.00810.1016/j.jconrel.2018.09.008 ↗
28. 10.1039/C8NR07424K10.1039/C8NR07424K ↗
29. 10.1039/C7NR02977B10.1039/C7NR02977B ↗
30. 10.1089/10445490275375971710.1089/104454902753759717 ↗
31. 10.1126/sciadv.aaw607110.1126/sciadv.aaw6071 ↗
32. 10.1038/s41467-023-37328-910.1038/s41467-023-37328-9 ↗
33. 10.3390/cancers1424609110.3390/cancers14246091 ↗
34. 10.1006/bcmd.1998.020110.1006/bcmd.1998.0201 ↗
35. 10.1038/nrc325810.1038/nrc3258 ↗
36. 10.1007/s00262-008-0489-210.1007/s00262-008-0489-2 ↗
37. 10.1038/ni75810.1038/ni758 ↗
38. 10.1038/ni0602-49910.1038/ni0602-499 ↗
39. 10.1038/s41586-018-0705-y10.1038/s41586-018-0705-y ↗
40. 10.1038/nri319310.1038/nri3193 ↗
41. 10.1038/nri378710.1038/nri3787 ↗
42. 10.1007/s00262-014-1523-110.1007/s00262-014-1523-1 ↗
43. 10.1016/j.intimp.2016.03.02510.1016/j.intimp.2016.03.025 ↗
44. 10.1016/j.actbio.2022.12.05810.1016/j.actbio.2022.12.058 ↗
45. 10.1021/nn502754c10.1021/nn502754c ↗
46. 10.1021/nn201950e10.1021/nn201950e ↗
47. 10.1074/mcp.E600005-MCP20010.1074/mcp.E600005-MCP200 ↗
48. 10.1038/nnano.2015.33010.1038/nnano.2015.330 ↗